2208-15-3

Basic information

• Product Name: 4-bromo-3-hydroxy-2-naphthoic acid
• Synonyms: 4-bromo-3-hydroxy-2-naphthoic acid;4-Bromo-3-hydroxy-2-naphthalenecarboxylic acid
• CAS NO: 2208-15-3
• Molecular Formula: C₁₁H₇BrO₃
• Molecular Weight: 267.07548
• EINECS: 218-632-2
• Mol File: 2208-15-3.mol
• Article Data: 8

Chemical Properties

• Melting Point: 231 °C
• Boiling Point: 377.3 °C at 760 mmHg
• Flash Point: 182 °C
• Appearance: /
• Density: 1.772 g/cm³
• Vapor Pressure: 2.31E-06mmHg at 25°C
• Refractive Index: 1.737
• Solubility: soluble in Methanol
• CAS DataBase Reference: 4-bromo-3-hydroxy-2-naphthoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-3-hydroxy-2-naphthoic acid(2208-15-3)
• EPA Substance Registry System: 4-bromo-3-hydroxy-2-naphthoic acid(2208-15-3)

Safety Data

• Hazardous Substances Data: 2208-15-3(Hazardous Substances Data)

Usage

General Description

4-bromo-3-hydroxy-2-naphthoic acid is a chemical compound with the molecular formula C11H7BrO3. It is a derivative of 2-naphthoic acid, a colorless organic compound used in the manufacture of dyes and fluorescent whitening agents. The presence of a bromine atom and a hydroxyl group on the naphthalene ring gives 4-bromo-3-hydroxy-2-naphthoic acid unique chemical properties and makes it suitable for various applications in organic synthesis and pharmaceutical research. 4-bromo-3-hydroxy-2-naphthoic acid is a potential candidate for the development of new drugs and has been studied for its anti-inflammatory and antioxidant properties. Additionally, it is used as a building block in the synthesis of more complex organic molecules.

InChI:InChI=1/C11H7BrO3/c12-9-7-4-2-1-3-6(7)5-8(10(9)13)11(14)15/h1-5,13H,(H,14,15)

Upstream product

• 92-70-6 3-Hydroxy-2-naphthoic acid 
• 7732-18-5 water 
• 7726-95-6 bromine 
• 67097-82-9 sodium 3-hydroxy-4-sulphonato-2-naphthoic acid 
• 124-38-9 carbon dioxide 
• 30478-89-8 1,3-dibromonaphthalen-2-ol 

Downstream Products

• 170889-47-1 diphenyl 2,2'-dihydroxy-[1,1'-binaphthalene]-3,3'-dicarboxylate 
• 1451072-11-9 C₂₆H₂₁ClO₂ 
• 1451072-10-8 methyl 4-(4-methoxyphenyl)-3-(p-tolyl)-2-naphthoate 
• 1451072-09-5 C₂₆H₁₉F₃O₂ 
• 1451072-08-4 C₁₈H₁₂BrClO₂ 
• 1451072-07-3 C₁₈H₁₂BrFO₂ 
• 1451072-06-2 C₁₉H₁₅BrO₂ 
• 1451072-05-1 C₁₉H₁₅BrO₂ 
• 1451072-04-0 C₂₀H₁₇BrO₂ 
• 1451072-03-9 methyl 4-bromo-3-(4-methoxyphenyl)-2-naphthoate 
• 1451072-02-8 C₂₆H₁₆F₆O₂ 
• 1451072-01-7 C₂₄H₁₆F₂O₂ 

Relevant articles and documents

Synthesis of linear and angular aryl-morpholino-naphth-oxazines, their DNA-PK, PI3K, PDE3A and antiplatelet activity

To continue our study of 2-morpholino-benzoxazine based compounds, which show useful activity against PI3K family enzymes or antiplatelet activity, we designed and synthesized a series of linear 6.7-fused, 5,6-angular fused and 7,8-angular fused-aryl-morpholino-naphth-oxazines. The compounds were prepared from substituted 2-hydroxynaphthoic acid to give the corresponding thioxo analogues 8, 9, 15 and 19. The thioxo products were then converted to the morpholino substituted analogue. The aryl group was introduced by Suzuki coupling of bromo precursors. The products were evaluated for activity at PI3K family enzymes and as platelet aggregation inhibitors and compared to reported unsubstituted analogues. The linear 6.7-fused product 13a and 13b were moderated potent but selective PI3Kδ isoform inhibitors (IC50?=?7.7 and 5.61?μM). Good antiplatelet activity was noticed for the angular 7,8-fused compounds 22a, b, k and l with IC50?=?3.0,14.0, 2.0 and 5.0?μM respectively. The antiplatelet activity is independent of PDE3.

Nickel-Catalyzed Directed Cross-Electrophile Coupling of Phenolic Esters with Alkyl Bromides

Herein, we demonstrate the successful use of robust phenolic esters as an electrophilic acyl source in the reaction with diverse primary and secondary unactivated alkyl bromides. The cleavage of the relatively inert C-O bond is facilitated by the neighboring coordinating hydroxyl or sulfonamide moiety. By circumventing the use of pregenerated organometallics, this method allows efficient preparation of a variety of o-hydroxyl and tosyl-protected o-amino aryl ketones with high compatibility with a wide range of functionalities.

PHAMACEUTICAL PREPARATIONS COMPRISING INSULIN

Novel preparations comprising ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer wherein the ligand is extended by protamine that are capable of prolonging the ac-tion of insulin preparations.